Contact

Our portfolio

Kling Biotherapeutics

Discovering antibody-based therapeutics, Kling Biotherapeutics targets cancer and infectious diseases. Their platform leverages patient immune repertoires to identify novel therapeutic targets. Kling Biotherapeutics has a rich pipeline of antibodies for oncology and infectious disease applications in clinical and preclinical development.

  • Institute: Amsterdam UMC
Industry: Infectious Disease, Oncology, Therapeutics
  • Founding year: 2021
Visit website

Want to get in contact about Kling Biotherapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Quantib
Enhancing patient care with AI-driven radiology solutions for clinical practice.

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.
Quantib
Enhancing patient care with AI-driven radiology solutions for clinical practice.

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.
Explore full AAV portfolio
Contact